A 2012 critique of cost-performance analysis for TCM observed that studies experienced low levels of proof, without beneficial results.[51] Pharmaceutical investigate about the possible for developing new medication from classic cures has number of thriving results.[two] Proponents suggest that analysis has to this point skipped key features from t